

DESCRIPTION


Species Reactivity	Human/Mouse
Specificity	Detects human and mouse Neurexin 3/NRXN3 in Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant human Neurexin 1 β is observed and less than 5% cross-reactivity recombinant rat (rr) Neurexin 1 α and rrNeurexin 2 β is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Neurexin 3/NRXN3 Ser35-Thr357 Accession # NP_620426
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 μ m filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	1 μ g/mL	See Below
Immunohistochemistry	5-15 μ g/mL	Immersion fixed paraffin-embedded sections of human brain (cerebellum and cortex)

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 $^{\circ}$ C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 $^{\circ}$C as supplied. ● 1 month, 2 to 8 $^{\circ}$C under sterile conditions after reconstitution. ● 6 months, -20 to -70 $^{\circ}$C under sterile conditions after reconstitution.

BACKGROUND

The alpha and beta forms of Neurexins 1-3 are transmembrane neuronal glycoproteins which are transcribed from each of three NRXN genes that utilize alternate promoters. Like other Neurexins, the extracellular domain (ECD) of Neurexin 3 α contains six LNS domains interspersed with three EGF-like domains, while that of Neurexin 3 β contains only the sixth LNS domain and no EGF-like domains (1-3). Mature human Neurexin 3 β is a 70 kDa glycosylated protein with a 528 amino acid (aa) ECD and a 56 aa cytoplasmic domain that contains a motif for binding PDZ scaffolding proteins (3-5). Within comparable regions of the ECD, human Neurexin 3 β shares 99% aa sequence identity with mouse and rat Neurexin 3 β . It shares 65% aa sequence identity with comparable regions of the ECD of human Neurexin 1 β and 2 β . Alternative splicing of human Neurexin 3 β generates multiple isoforms. There are potentially soluble and secreted variants and some which contain a fibronectin type III-like domain (4, 6). Neurexin 3 β is widely expressed in the brain where it binds the postsynaptic Neuroligins 1, 2, and 3 (6-9). Neurexin 3 β may also be expressed in non-nervous tissues with a potentially cardiac-specific isoform (10). Human Neurexin 3 β polymorphisms which affect the splicing pattern are associated with susceptibility to alcohol dependence (6). The Neurexin 3 β genetic locus has been linked to opioid and nicotine addiction, and Neurexin 3 β gene expression is up-regulated after short term exposure of mice to cocaine (11-13).

References:

1. Craig, A.M. and Y. Kang (2007) *Curr. Opin. Neurobiol.* **17**:43.
2. Dean, C. and T. Dresbach (2006) *Trends Neurosci.* **29**:21.
3. Lise, M.-F. and A. El-Husseini (2006) *Cell. Mol. Life Sci.* **63**:1833.
4. Rowen, L. *et al.* (2002) *Genomics* **79**:587.
5. Ushkaryov, Y. A. *et al.* (1994) *J. Biol. Chem.* **269**:11987.
6. Hishimoto, A. *et al.* (2007) *Hum. Mol. Genet.* **16**:2880.
7. Ullrich, B. *et al.* (1995) *Neuron* **14**:497.
8. Ichtchenko, K. *et al.* (1996) *J. Biol. Chem.* **271**:2676.
9. Ichtchenko, K. *et al.* (1995) *Cell* **81**:435.
10. Occhi, G. *et al.* (2002) *Biochem. Biophys. Res. Commun.* **298**:151.
11. Lachman, H.M. *et al.* (2007) *Hum. Mol. Genet.* **16**:1327.
12. Bierut, L.J. *et al.* (2007) *Hum. Mol. Genet.* **16**:24.
13. Kelai, S. *et al.* (2008) *Neuroreport* **19**:751.